ADAM9 and adenocarcinoma: In the present study, 52 (72.2%) squamous cell carcinoma, 18 (25.0%) adenocarcinoma and 2 (2.8%) adenosquamous cell carcinoma samples were positive for ADAM9 immunostaining (Table 2).